$AXON

Williams Jeri sold $102K of AXON

Williams Jeri sold 223 shares of AXON ENTERPRISE, INC. (AXON) at $455.45 ($0.10M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Jeri
Published Jun 2, 2026, 9:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
medium confidence
Mentioned
$AXON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity, but the pre-arranged nature generally limits interpretability for near-term trading decisions.

02

Market read

Useful for tracking insider behavior, but not a standalone fundamental catalyst for AXON.

03

What to watch

The filing does not reveal intent beyond the plan; consider the director’s broader trading history and whether other insiders filed around the same time.

Relevance 4/10Novelty 2/10Timing: Filed after-hours/late day (2026-06-02) for a sale executed 2026-06-01.

Background

This is an SEC Form 4 insider transaction disclosure for AXON, reporting an open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$AXONNeutralMedium confidence
Context

Director Williams Jeri filed an open-market sale of 223 AXON shares under a pre-arranged 10b5-1 plan on 2026-06-01.

Expected impact

Low likelihood of a sustained price move from this filing alone; any impact is likely limited to short-term sentiment.

Evidence & confidence

The transaction is an open-market sale and explicitly tied to a pre-arranged 10b5-1 plan, which reduces informational content versus unscheduled sales.

Market effects

Minimal—single-company insider transaction without accompanying operational or financial catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated or sizable insider sales can coincide with periods of valuation risk or personal liquidity needs—monitor for clustering of similar filings.

Key entities

  • AXON ENTERPRISE, INC.

    Issuer of the reported insider transaction (director sale) disclosed via SEC Form 4.

  • Williams Jeri

    Director who sold 223 shares of AXON on 2026-06-01 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.